# Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

> **NCT00716456** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Lung Adenocarcinoma

## Interventions

- **DRUG:** erlotinib with cetuximab

## Key facts

- **NCT ID:** NCT00716456
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2015-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00716456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00716456, "Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00716456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*